GV-58 60427 A major challenge of the

A major challenge of the current hESC/iPSC differentiation paradigm is the inability to effectively capture and long-term

a novel EP4 antagonist: receptor binding

InChi: InChI=1S/C14H7Cl2NO3/c15-9-3-8(4-10(16)6-9)13-17-11-2-1-7(14(18)19)5-12(11)20-13/h1-6H

The direct target of KY02111 remains unknown

Chemical Name: (S)-3-(1H-indol-3-yl)-N-((1-(4-methoxyphenyl)cyclohexyl)methyl)-2-(3-(4-nitrophenyl)ureido)propanamide

GV-58 60427 A major challenge of theGV 58 is a potent, selective N and P Q type Ca2+ channels agonist with EC50 of 7. 21 8. 81 uM for N type P Q type Ca2+ channel; 20 fold less potent CDK inhibitor activity. IC50 value: 7. 21 8. 81 uM (N type P Q type Ca2+ channel) Target: Ca2+ channel agonistIn comparison with the parent molecule, (R) roscovitine, GV 58 has a 20 fold less potent cyclin dependent kinase antagonist effect, a 3 to 4 fold more potent Ca2+ channel agonist effect, and 4 fold